Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
33 Leser
Artikel bewerten:
(0)

Heygood, Orr, Reyes & Bartolomei: $5.5 Million Award in First Federal Fentanyl Patch Trial


WEST PALM BEACH, Fla., June 19 /PRNewswire/ -- The family of a Florida man has won a $5.5 million wrongful death verdict against two subsidiaries of pharmaceutical giant Johnson & Johnson in the nation's first federal trial involving a patch form of the narcotic painkiller fentanyl.

The 2-man, 6-woman jury deliberated for 11 hours over two days before returning their verdict earlier today in the U.S. District Court for the Southern District of Florida.

Janssen Pharmaceutica Products, LP, and ALZA Corp. were sued by the family of 28-year-old Adam Hendelson following his death on Dec. 17, 2003. Both companies are subsidiaries of New Brunswick, N.J.-based Johnson & Johnson.


Mr. Hendelson suffered chronic hip pain as a result of an automobile accident, and wore a Duragesic(R) patch on his right arm. Duragesic is the brand name of a transdermal patch that contains a gel form of the drug fentanyl, an opium-like substance that is up to 100 times stronger than morphine.

"In essence, the jury found that Adam Hendelson did not have to die," said Jim Orr of Dallas' Heygood, Orr, Reyes & Bartolomei, attorney for the Hendelson family. "The facts and the evidence clearly showed that Janssen and ALZA knew that problems with the Duragesic patches could hurt or kill someone, and in Adam's case, that's exactly what happened."

Also representing the Hendelson family were Mr. Orr's partners Angel Reyes and Charles Miller, along with attorneys Ike Gulas, Jason Stuckey, and Ed Angwin from the Birmingham, Ala., firm of Gulas & Stuckey, P.C.

Janssen and ALZA both manufacture and sell Duragesic patches, which accounted for $1.5 billion in total sales in 2005. In June 2005, more than a year after Mr. Hendelson's death, the defendants issued new health warnings regarding the use of Duragesic.

Heygood, Orr, Reyes & Bartolomei is an AV-rated firm that focuses its practice on the representation of plaintiffs in business disputes, civil litigation matters, and more. With 11 attorneys and a staff of 50, the firm's trial teams handle a full array of civil litigation and business cases across Texas and the United States.

More information is available at http://www.reyeslaw.com/.

For more information on the verdict, please contact Mark Annick at 800-559-4534 (office), 214-213-1754 (mobile) or mark@legalpr.com.
Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2007 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.